Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy
Radiation Oncology Journal 2013³â 31±Ç 3È£ p.111 ~ p.117
°Çöö(Kang Hyun-Cheol) - Seoul National University College of Medicine Department of Radiation Oncology
¿ìÈ«±Õ(Wu Hong-Gyun) - Seoul National University College of Medicine Department of Radiation Oncology
(Yu To-Sol) - Seoul National University College of Medicine Department of Radiation Oncology
±èÇÐÀç(Kim Hak-Jae) - Seoul National University College of Medicine Department of Radiation Oncology
ÆØÁøö(Paeng Jin-Chul) - Seoul National University College of Medicine Cancer Research Institute
Abstract
Purpose: To determine whether the maximum standardized uptake value (SUV) of [18F] fluorodeoxyglucose uptake by positron emission tomography (FDG PET) ratio of lymph node to primary tumor (mSUVR) could be a prognostic factor for node positive non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy (RT).
Materials and Methods: A total of 68 NSCLC T1-4, N1-3, M0 patients underwent FDG PET before RT. Optimal cutoff values of mSUVR were chosen based on overall survival (OS). Independent prognosticators were identified by Cox regression analysis.
Results: The most significant cutoff value for mSUVR was 0.9 with respect to OS. Two-year OS was 17% for patients with mSUVR > 0.9 and 49% for those with mSUVR ¡Â 0.9 (p = 0.01). In a multivariate analysis, including age, performance status, stage, use of chemotherapy, and mSUVR, only performance status (p = 0.05) and mSUVR > 0.9 (p = 0.05) were significant predictors of OS. Two-year OS for patients with both good performance (Eastern Cooperative Oncology Group [ECOG] ¡Â 1) and mSUVR ¡Â 0.9 was significantly better than that for patients with either poor performance (ECOG > 1) or mSUVR > 0.9, 23% (71% vs. 23%, p = 0.04).
Conclusion: Our results suggested that the mSUVR was a strong prognostic factor among patients with lymph node positive NSCLC following RT. Addition of mSUVR to performance status identifies a subgroup at highest risk for death after RT. Keywords: Non-small-cell lung carcinoma, Radiotherapy, Positron-emission tomography, Prognosis
Å°¿öµå
Non-small-cell lung carcinoma, Radiotherapy, Positron-emission tomography, Prognosis
KMID :
1038620130310030111
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The most significant cutoff value for mSUVR was 0.9 with respect to overall survival (OS). Two-year OS was 17% for patients with mSUVR > 0.9 and 49% for those with mSUVR ¡Â 0.9 (p = 0.01); The mSUVR was a strong prognostic factor among patients with lymph node positive NSCLC following RT.